BCL2 and cancer: As previously shown in other cancer cohorts12,22, MCL-1 gains did not elicit compensatory dysregulation of other BCL-2 family members in LUAD, irrespective of the cohort analysed (TRACERx or TCGA, Supplementary Fig. 8a, b).